Results 151 to 160 of about 53,817 (192)

Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis. [PDF]

Front Oncol
Neira D, Ruiz P, Nuñez B, Navarrete G, Vasquez R, Villanueva L, Barajas O.   +6 more
europepmc   +1 more source

Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer. [PDF]

Cell Commun Signal
Chen WY, Huang KH, Kajla G, Wen YC, Liu MK, Fan YC, Dung PVT, Yeh HL, Chen WH, Jiang KC, Li HR, Chen CS, Huang J, Beltran H, Liu YN.   +14 more
europepmc   +1 more source

Pyridopyrimidines and Pyridopyrimidinones as Kinase-Targeted Anticancer Agents: Medicinal Chemistry and Mechanistic Insights. [PDF]

Molecules
Kumar A, Kaur R, Kumar B, Bhatia R.
europepmc   +1 more source

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers. [PDF]

Int J Clin Oncol
Lee J, Sim J, Lee YG, Lee GW, Jung HA, Kim KP, Kim TY, Ryu H, Ryu MH, Ahn MS, Kwon M, Keam B, Bae JM, Kim S, Koo H, Kim SY, Kim JH, Lee S.   +17 more
europepmc   +1 more source

HDAC1 Regulates Acquired Resistance to EGFR Inhibitors through the TFCP2-NDRG1 Signaling Axis in Pancreatic Cancer. [PDF]

Int J Biol Sci
Chen T, Li Y, Sun Y, Fu Q, Wu H, Li D, Ren D.   +6 more
europepmc   +1 more source

Hypomagnesemia in patients on oral EGFR tyrosine kinase inhibitors: renal magnesium wasting or concurrent confounders? [PDF]

Clin Kidney J
Ilyas M, Nguyen J, Shettigar S, Rathi K, Kim E, LeClaire J, Mathavan A, Mathavan A, Fares A, Shah CV.   +9 more
europepmc   +1 more source

ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response. [PDF]

JCO Precis Oncol
Peshin S, Saj F, Kasi PM, David F, Szklaruk J, Kimana Q, Pant S, Lee SS, Knox JJ, Borad MJ, Javle M.   +10 more
europepmc   +1 more source

Titanium dioxide nanoparticle-modified screen-printed electrode for erlotinib determination. [PDF]

ADMET DMPK
Manjulabhai PD, Mundangadan S, Paul M, Lal S, Ramalal N, Anto M, Gangadharan D.   +6 more
europepmc   +1 more source

Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk. [PDF]

Neurotherapeutics
Malaty GR, Killion JA, Doddamreddy SA, Laurido-Soto OJ, Racette BA.   +4 more
europepmc   +1 more source